Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03844269 · ClinicalTrials.gov registry record · NA
Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01
A NA study of Attention Deficit Hyperactivity Disorder, sponsored by Akili Interactive Labs.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03844269: Completed NA study of Attention Deficit Hyperactivity Disorder, sponsored by Akili Interactive Labs.
NCT03844269 is a NA study of Attention Deficit Hyperactivity Disorder that has completed, run by Akili Interactive Labs. The registered enrollment target is 28 participants, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03844269, a NA study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Akili Interactive Labs.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single arm, open-label, pilot study to assess midline frontal theta (MFT) power as measured by stimulus-locked electroencephalogram (EEG) before and after treatment with AKL-T01 for improving attention in pediatric participants ages 8-12 years old with attention deficit hyperactivity disorder (ADHD).
Primary Outcome
Change in midline frontal theta (MFT) power as measured by Perceptual Discrimination Task (PDT)-Locked Electroencephalogram (EEG).
Conditions Studied
Interventions
- DEVICE AKL-T01
Study Locations (1)
California
- Cortica Healthcare - San Rafael
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-05-10 |
| Est. Completion | 2020-02-01 |
| Phase | NA |
What the finished NCT03844269 record still lists
NCT03844269 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which AKL-T01 is the first listed.
NCT03844269 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03844269 about?
NCT03844269 is a clinical study titled "Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01". This study is a single arm, open-label, pilot study to assess midline frontal theta (MFT) power as measured by stimulus-locked electroencephalogram (EEG) before and after treatment with AKL-T01 for improving attention in pediatric participants ages 8-12 years old with attention deficit hyperactivity...
What is the current status of trial NCT03844269?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2019-05-10. Estimated completion is 2020-02-01.
What conditions does trial NCT03844269 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT03844269?
The interventions under investigation include: AKL-T01 (DEVICE).
Who is sponsoring clinical trial NCT03844269?
This trial is sponsored by Akili Interactive Labs, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03844269 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03844269's enrollment target sits among peer trials
28 90th of 102 higher than 11 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HOPS Study: A Conceptual Replication
RECRUITING · NA
-
Acute Effects of Exercise in College Students With ADHD
RECRUITING · NA
-
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
RECRUITING · NA
-
ADHD PreSMA Response Inhibition Therapy
RECRUITING · NA
-
Mindfulness Intervention for College Students With ADHD
RECRUITING · NA
-
BUILT Family Lifestyle Program for Children with ADHD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI